Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $490,160.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total value of $490,160.00. Following the transaction, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at approximately $5,862,252.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $69.02, for a total value of $552,160.00.

Vaxcyte Trading Down 1.0 %

Shares of Vaxcyte stock opened at $60.30 on Thursday. Vaxcyte, Inc. has a twelve month low of $41.57 and a twelve month high of $82.04. The stock has a market capitalization of $6.56 billion, a P/E ratio of -14.60 and a beta of 0.89. The business’s fifty day moving average price is $68.55 and its 200 day moving average price is $61.28.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter in the previous year, the business posted ($0.73) earnings per share. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $95.00 price objective on shares of Vaxcyte in a report on Wednesday, April 10th. Bank of America raised their price objective on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $78.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PCVX. Allspring Global Investments Holdings LLC lifted its stake in shares of Vaxcyte by 1,005.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 22,603 shares of the company’s stock worth $1,419,000 after purchasing an additional 20,558 shares in the last quarter. Mutual of America Capital Management LLC acquired a new position in shares of Vaxcyte during the fourth quarter worth about $3,035,000. Wellington Management Group LLP lifted its stake in shares of Vaxcyte by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock worth $234,442,000 after purchasing an additional 167,501 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of Vaxcyte by 20.6% during the third quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock worth $89,454,000 after purchasing an additional 300,189 shares in the last quarter. Finally, UBS Group AG lifted its stake in shares of Vaxcyte by 62.2% during the third quarter. UBS Group AG now owns 74,305 shares of the company’s stock worth $3,788,000 after purchasing an additional 28,483 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.